key: cord-0311325-ppwiwf1t
authors: Fedrizzi, E. N.; Girondi, J. B. R.; Sakae, T. M.; Steffens, S. M.; Silvestrin, A. N. d. S.; Claro, G. S.; Iskenderian, H. A.; Hillmann, B.; Gervasi, L. C.; Trapani, A.; Rodrigues, P. d. A.; Vieira, A. d. S.; Evaristo, S. M.; Tristao, F. R.; Muniz, F. d. S.; Nunes, M. V.; Beatriz, N. Z.; Elpo, J.; Tiedje, A.; Siqueira, L. S.; Sens, M.; Nandi, V.; Pereira, J. G.; Henrique, G. C.; de Carvalho, A. P. F.; de Morais, R. C. P.; de Cristo, G. G.; Hochsprung, M. E.; Morais, A. C.; Centenaro, R.; Garcia, A.; Silva, B. H.; Ouriques Neta, E. L.; Ferreira, M. E. A.; Hames, M. E.; Gubert, M. E. P.; Calegari,
title: EFFICACY OF THE MEASLES-MUMPS-RUBELLA (MMR) VACCINE IN THE REDUCING THE SEVERITY OF COVID-19: AN INTERIM ANALYSIS OF A RANDOMISED CONTROLLED CLINICAL TRIAL
date: 2021-09-20
journal: nan
DOI: 10.1101/2021.09.14.21263598
sha: d2693e5ecff4a0fd6ae893ba186235fe1f63b3dd
doc_id: 311325
cord_uid: ppwiwf1t

Background: COVID-19 is still a challenge, both with regard to its treatment and to the actual efficacy of the vaccines available to date, especially with the emergence of new variants. We evaluated the efficacy of the measles-mumps-rubella (MMR) vaccine in preventing SARS-CoV-2 infection and severity of COVID-19 in health workers. Methods: This analysis includes data from one ongoing blinded, randomized, placebo-controlled trial with participants aged 18-60 years were randomly assigned to receive the MMR vaccine or a placebo. The primary efficacy analysis included all participants with a positive nasopharyngeal RT-PCR test since their inclusion. Results: The MMR vaccine did not prevent the SARS-CoV-2 infection. Participants in the MMR group, compared with those in the placebo group, had a 48% risk reduction in symptomatic COVID-19 (RR = 0.52; 95% CI: 0.33-0.83; p=0.004) and a 76% risk reduction in COVID-19 treatment (RR = 0.24; 95% CI: 0.06-0.88; p = 0.020) with one dose and a 51% risk reduction in COVID-19 symptoms (RR = 0.49; 95% CI: 0.31 - 0.78; p = 0.001) and a 78% risk reduction in COVID-19 treatment (RR = 0.22; 95% CI: 0.06-0.82; p = 0.015) with two doses. Conclusions: This interim analysis of an ongoing clinical trial suggests that compared with a placebo, the vaccine reduces the risk of COVID-19 symptoms and reduces the need for COVID-19 treatment.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021.

In December 2019, China began to observe cases of severe acute respiratory syndrome caused by a novel coronavirus (severe acute respiratory syndrome coronavirus 2 -SARS-CoV-2), later named coronavirus disease 2019 (COVID-19) [1] . This infection spread rapidly around the world and was declared a pandemic by the World Health Organization (WHO) on March 11, 2020 , the first pandemic caused by a coronavirus [2] .

Recent studies have shown that possibility the greater the amount of virus inhaled by an individual, the higher the viral load and perhaps the greater the severity of the disease. SARS-CoV-2 has the ability to inhibit the immune response, especially the production of interferons, which may facilitate this increase in the viral load [3] [4] [5] [6] . The most effective way to reduce severe cases and deaths is through the prevention of SARS-CoV-2 infection using a vaccine. However, although vaccines are already being administered in several countries, vaccination of the entire indicated population, especially in less developed countries, is not expected in the next few years.

Some studies have raised the possibility of using some vaccines to improve the immune response, such as BCG, measles or triple viral (measles, mumps and rubella), oral poliomyelitis or other vaccines, preferably with live attenuated antigen, due to their robust and long-. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint lasting immune response [7] [8] [9] . This nonspecific immune response produces a potent protective barrier that can prevent cell invasion by another virus [10, 11] .

The objective of using a vaccine with live and attenuated microorganisms is to stimulate the innate immune response; repeated exposure to the antigen (innate immune response training) results in an extension of the action time of this immune response (innate immune response memory) and consequently in protection against other infections (heterologous immunity) for a longer time [7, 8, [10] [11] [12] [13] [14] [15] .

Even if this effect lasts for a limited period of time, it can greatly contribute to reducing the spread of infection in the early stages of a pandemic and/or reducing the severity of the disease, thus preventing hospitalizations and deaths [10, 12, [16] [17] [18] . Therefore, if one of these vaccines does not completely prevent infection, it could reduce the inhaled viral load and reduce the severity of COVID-19. This possible heterologous immunity of the measles-mumps-rubella (MMR) vaccine may be associated with potent stimulation of innate immunity, leading to a decrease in viral load via cellular immunity [10, 13, 14, 16] and possible humoral immunity due to some similarities between the glycoproteins of the measles and rubella viruses and SARS-CoV-2 [9, 19] and the action of antibodies against mumps [20] .

The objective of this study was to evaluate whether the MMR vaccine, compared with a placebo, protects against COVID-19 or at least . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint decreases the symptoms and severity of this infection in health workers. All study volunteers met all of the following criteria to participate in the study (inclusion criteria): 1) male and female health workers aged 18 to 60 years (inclusive) at the first visit (V1); 2) volunteers who, in the opinion of the researchers, were able to meet the requirements of the study protocol. The following exclusion criteria were used to select volunteers at V1: 1) women who were pregnant or wishing to become pregnant during the study period; 2) women who were breastfeeding;

3) individuals with immune system deficiency or receiving or had received treatments such as chemotherapy, radiotherapy, high corticosteroid doses (>20 mg/day for ≥14 days) or immunosuppressants in the past 90 days; 4) individuals who received . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

A total of 430 health workers were included in the study. The participants selected for the study were mainly COVID-19 frontline health workers, of both sexes, aged between 18 and 60 years. The is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint participants were divided into 2 groups randomly allocated at a 1.5:1 ratio, with the MMR group consisting of 246 volunteers and the placebo group (saline solution) consisting of 178 volunteers. Randomisation list was prepared by the study statistician (TMS) and washeld by the unmasked study nurse who prepared the vaccines for administration, with all other trial staff masked to group allocation. The vaccine and placebo were prepared out of sight of the participants and all study staff and syringes were covered with an opaque material until ready for administration.

Those participants with a negative rapid test underwent sample collection from the nasopharynx for SARS-CoV-2 RT-PCR testing and received the appropriate injection (vaccine or placebo); the same occurred at V3 (after 60 days), when the participants received the second injection. The volunteers received two doses, at an interval of 8 weeks of 0.5 mL of subcutaneous MMR vaccine or placebo. The MMR vaccine used in this study was manufactured by Fiocruz -Biomanguinhos Laboratory (Rio de Janeiro, Brazil) and contains three live attenuated viruses that are highly immunogenic, providing lasting protection for most vaccinated individuals after two doses [21, 22] . It was licenced for commercialization in the 1970s and included in vaccination schedules in the Americas and Europe at the same time is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. [22] . The MMR vaccine is highly safe and minimally reactive, has minimal side effects and is widely used around the world [15] . Adverse reactions are rarely observed after its administration [21, 22] . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint

The first primary endpoint was the efficacy of the MMR vaccine against symptomatic COVID-19 confirmed in participants with symptoms (at least one symptom, such as fever, cough, laboured breathing, chills, painful swallowing, muscle ache, loss of smell, loss of taste, diarrhoea or vomiting) and a positive RT-PCR test. The secondary endpoints were preventing SARS-CoV-2 infection, as confirmed by RT-PCR, in participants with or without symptoms and the efficacy of the MMR vaccine against moderate and severe COVID-19.

We also evaluated whether there was a significant difference between the groups with or without COVID-19 regarding sex, age, race, profession, adverse events and associated comorbidities.

Assuming an expected infection rate of 20% in the group not exposed to vaccination and 10% in the vaccinated group, with an alpha error of 5%, power of 80%, and group ratio of 1.5:1, the calculated minimum sample size required was 405 volunteers. Adding a risk of unexpected losses of 5%, the minimum sample size required for this study was 420 volunteers. Our study included 430 volunteers. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint of the rate of individuals with COVID-19 in group 1 (MMR vaccine) over the rate of individuals with COVID-19 in group 2 (control).

In the Intention-to-treat population analysis (ITT), all randomised study participants were included. The observation time started when the first dose of the vaccine/placebo was administered. Model based multiple imputation (MI) was used for both primary and secondary outcomes.

A Per-Protocol analysis (PP) was performed with all randomised study participants completing the whole study period (complete cases). For a specific analysis, study participants with missing data on any of the variables in the model was excluded from the analysis.

The reduction in COVID-19 severity was evaluated by comparing cases of asymptomatic, mild, moderate and severe disease between the group that received the MMR vaccine and the group that received placebo.

In the period from 29 July 2020 to 20 February 2021, a total of 430 health workers aged 18 to 60 years were selected for the study. Of these, six were excluded for having a positive rapid test for SARS-CoV-2. A total of 424 participants were randomly allocated to receive the MMR vaccine or placebo. A total of 246 volunteers from the vaccine group and 178 from the placebo group received at least one dose. All is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint of these participants were included in the efficacy analysis, with a median follow-up of five months (Fig. 1 ). Of these 424 participants, 76% were women, and 89% were white. The mean age was 38 years, with 15% being over 50 years old. Among the health workers, 23%

were doctors, 23% were health technicians and 21% were nurses. The most frequent comorbidities among the participants were hypertension (9.4%) ( Table 1 ). There were six cases (5.8%) of probable reinfection, all with positive RT-PCR tests at an interval of more than three months, interspersed with negative tests. All participants were asymptomatic or had mild symptoms. It was not possible to perform genetic sequencing.

Another eight participants (7.8%) had positive RT-PCR results for two or three months (Table S1 ).

There was no significant difference in sex, race, age or profession when evaluating the cases of COVID-19. When assessing comorbidities, hypertension, obesity and pneumopathy were the most frequent in both groups. However, we observed a higher risk of participants with diabetes mellitus becoming infected with SARS-CoV-2 (RR = 11.04; 95% CI: 2.33-52.35; p = 0.0009) ( Table 2) .

Among the 424 participants who entered the study and received at least one dose of the MMR vaccine or placebo, there were 102 cases of COVID-19, with no significant difference in cases of infection between the groups (RR = 0.91; 95% CI: 0.65-1.28; p = 0.348) ( Table 3) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint

Of the total number of RT-PCR-positive cases in each group, we observed a higher frequency of asymptomatic cases in the MMR group (12.19%) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint either local or systemic, were reported in the study in the vaccinated group or placebo group (Table S2) .

The administration of at least one dose of the MMR vaccine resulted in a significant reduction of 48% in symptomatic COVID-19 and of 76% in the need for treatment. When the participant used two doses, the reduction was 51% and 78%, respectively. These results confirm several previous studies that observed a reduction of infections through heterologous immunity via stimulation of innate immunity by attenuated vaccines [7, [13] [14] [15] and specifically by the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint rubella virus have an amino acid sequence with 29% identity.

Hypothetically, these SARS-CoV-2 macrodomains could be recognized by anti-rubella antibodies and provide a certain degree of protection.

One study showed that the levels of antibodies against rubella (IgG) increased in patients with COVID-19, similar to cases of a second infection with rubella [19] . 5) There is significant evidence of an inverse correlation between the levels of antibodies against mumps and COVID-19 severity, i.e., the higher the concentration of anti-mumps IgG antibodies, the lower is the severity of COVID-19 [20] .

The duration of protection of heterologous immunity is not yet well defined. In our study, the median follow-up was 5 months. Several studies have shown that the memory of innate immunity (stimulated by innate immunity training) may last for 1 year or more [16, 30] .

This study had some limitations. Although the number of participants was small, the median follow-up of five months was sufficient for a statistical analysis to demonstrate significance. A second issue to address is the duration of the action of the MMR vaccine in COVID-19 disease progression. We still do not know how long it lasts, but the study is still ongoing to try to answer this question. It would be extremely important to have evaluated the cellular immune response and viral load between the vaccinees and placebo, as this would be an indicator of the effectiveness of MMR vaccine in inducing innate immune responses that could reduce viral load. We were unable to . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint conducted genetic sequencing of suspected cases of reinfection due to laboratory challenges. We did not have information on the dosages of antibodies in the individuals who developed COVID-19 and were vaccinate or not with MMR. It was not possible to perform the genotyping of Sars-CoV-2 in infected patients to assess the possible variants. The age range evaluated was 18-60 years, and we cannot guarantee that the observed results will be the same in people above and below these ages. The results of the trial were obtained from health workers, who are generally healthy and it is not possible to extrapolate these same results to the general population.

The results of this analysis showed that the MMR vaccine can is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint

All authors declare no competing interests. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint All authors approved the final version of the manuscript and had access to the relevant study data and related analyses and vouch for the completeness and accuracy of the data presented.

The results of this study are preliminary and the study is ongoing. A complete de-identified patient dataset will be available upon completion of clinical trials and publication of the results of the completed study upon request to the corresponding author. Proposals will be reviewed and approved by the MMRCoV Study group on the basis of scientific merit and absence of competing interests. Once the proposal has been approved, data will be transferred after the signing of a data access agreement and a confidentiality agreement.

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint ¶ In the per-protocol population 222 participants in the vaccine group and 152 participants in the placebo group received two vaccine or placebo doses and did not violate the protocol.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint Table S1 . Positive PCR results at more than 1 visit among MMRCoV clinical trial participants. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 20, 2021. ; https://doi.org/10.1101/2021.09.14.21263598 doi: medRxiv preprint

A novel coronavirus from patients with pneumonia in China

World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID 19 -11

SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression

Therapeutic targeting of trained immunity

Measles vaccination and child mortality

Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial

Nonspecific effects of vaccines on childhood mortality

Thirty-six COVID-19 cases preventively vaccinated with mumps-measles-rubella vaccine: All mild course

Homologous protein domains in SARS-CoV-2 and measles, mumps and rubella viruses: preliminary evidence that MMR vaccine might provide protection against COVID-19

Analysis of measles-mumps-rubella (MMR) titers of recovered COVID-19 patients

Instituto de Tecnologia em

Federação Brasileira das Associações de Ginecologia e

We would like to thank the Federal University of Santa Catarina (UFSC) and Santa Catarina State Research and Innovation Foundation (FAPESC) for financing the study; University Hospital Prof Polydoro